REGN2477+REGN1033

Phase 2Small molecule

Regeneron

REGN2477+REGN1033 is one of 14 small molecule programs targeting Inclusion Body Myositis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Inclusion Body MyositisActive, not recruiting

Inclusion Body MyositisPhase 2

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Inclusion Body Myositis

#DrugCompanyPhaseTrials

Rapamune

PPrism Pharmaceuticals

Bimagrumab

1 3

Jakafi

Incyte

Phase 2

1 4

Rapamycin

MMaastricht Radiation Oncology

Phase 3

1 5

Campath

GGenzyme, a Sanofi Company

Phase 2

1 6

Miplyffa

ZZevraDenmark

Phase 2

3 7

Tysabri

Biogen

Phase 1

1 8

Actos

Takeda

Phase 1

1 9

BYM338

Novartis

Phase 2

2 10

ABC008

AAbcuro, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Inclusion Body Myositis1 trial

Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

Withdrawn· Regeneron logo

Regeneron·Phase 2·NCT03710941

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for REGN2477+REGN1033. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REGN2477+REGN1033 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REGN2477+REGN1033. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Regeneron

REGN2477+REGN1033

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Inclusion Body Myositis1 trial

References

Drug Info

Quick Facts

Related News